STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW
Starling Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.46+0.03 (+0.47%)
Close on Oct 19, 2026
- Market cap
- $665.58M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
40M
Shares held, 13F filers
Institutional holders
120
27 new, 21 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
16 buys · 11 sales
Net sold $122.18K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| M33 Growth I GP LLC | 9,290,838 | 9.79% | 13D (active) amendment | Sep 4, 2025 |
| M33 Growth I LP | 6,802,656 | 5.46% | 13D (active) amendment | Nov 18, 2025 |
| Chernett Jorey | 10,115,944 | 10.20% | 13G (passive) amendment | Mar 13, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of STLN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,749,030 | – | $25.79M | +333,163 | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 3,360,052 | – | $18.25M | – | 0.19% |
| Vanguard Capital Management LLC | 3,265,531 | – | $17.73M | −211,250 | 0.00% |
| Josh Arnold Investment Consultant, LLC | 2,464,359 | – | $13.38M | – | 8.42% |
| Geode Capital Management, LLC | 1,899,998 | – | $10.32M | +142,151 | 0.00% |
| Goldman Sachs Group Inc | 1,735,337 | – | $9.42M | +383,438 | 0.00% |
| Wexford Capital LP | 1,711,323 | – | $9.29M | – | 1.19% |
| State Street Corp | 1,552,917 | – | $8.43M | +91,463 | 0.00% |
| Nuveen, LLC | 1,408,720 | – | $7.65M | +1,313,456 | 0.00% |
| Renaissance Technologies LLC | 1,365,913 | – | $7.42M | +463,104 | 0.01% |
| CenterBook Partners LP | 1,241,660 | – | $6.74M | −326,763 | 0.33% |
| Marshall Wace, Llp | 1,222,498 | – | $6.64M | +880,233 | 0.01% |
| Vanguard Portfolio Management LLC | 1,007,037 | – | $5.47M | +144,198 | 0.00% |
| Citadel Advisors LLC | 894,101 | – | $4.85M | +285,834 | 0.00% |
| Jane Street Group, LLC | 852,163 | – | $4.63M | +427,269 | 0.00% |
| B. Riley Financial, Inc. | 742,593 | – | $4.03M | −187,141 | 0.93% |
| Arrowstreet Capital, Limited Partnership | 710,888 | – | $3.86M | +291,465 | 0.00% |
| Two Sigma Investments, LP | 668,839 | – | $3.63M | +361,085 | 0.00% |
| Northern Trust Corp | 591,534 | – | $3.21M | +33,079 | 0.00% |
| Acadian Asset Management LLC | 567,001 | – | $3.07K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 120 | 40M | 27 / 51 | 25 / 21 | 10M | 8M |
| Q1 2026 | 115 | 39M | 25 / 51 | 27 / 26 | 11M | 6M |
| Q4 2025 | 117 | 38M | 29 / 47 | 26 / 18 | 8M | 5M |
| Q3 2025 | 108 | 35M | 35 / 34 | 23 / 6 | 11M | 8M |
| Q2 2025 | 79 | 32M | 42 / 24 | 4 / 6 | 17M | 2M |
| Q1 2025 | 43 | 17M | 15 / 8 | 7 / 3 | 4M | 1M |
| Q4 2024 | 31 | 15M | 5 / 9 | 3 / 8 | 1M | 7M |
| Q3 2024 | 34 | 21M | 3 / 12 | 7 / 6 | 5M | 1M |
| Q2 2024 | 39 | 19M | 4 / 9 | 13 / 12 | 2M | 1M |
| Q1 2024 | 47 | 17M | 7 / 14 | 12 / 5 | 1M | 2M |
| Q4 2023 | 45 | 18M | 13 / 14 | 9 / 3 | 4M | 0M |
| Q3 2023 | 36 | 15M | 9 / 11 | 10 / 11 | 2M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of STLN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,395,214 | – | $13.01M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,000,935 | – | $10.87M | 0.01% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 1,029,230 | – | $5.00M | 0.12% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 838,318 | – | $4.07M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 794,687 | – | $4.32M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 550,738 | – | $2.99M | 0.02% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 409,553 | – | $1.92M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 354,935 | – | $1.66M | 0.00% | May 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 278,966 | – | $1.31M | 0.07% | May 31, 2026 |
| iShares Micro-Cap ETF | 257,181 | – | $1.40M | 0.09% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 191,890 | – | $1.04M | 0.00% | Jun 30, 2026 |
| Tiff Multi-Asset Fund | 188,873 | – | $1.03M | 0.07% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 185,962 | – | $903.78K | 0.01% | Jul 31, 2026 |
| Goldman Sachs Small Cap Equity Insights Fund | 159,056 | – | $773.01K | 0.08% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 150,570 | – | $817.60K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Yale Podnos | Chief Medical Officer | 277,501 | Jul 16, 2026 |
| Robert Ross Carter | Chief Financial Officer | 649,975 | May 22, 2026 |
| Daniel Virnich | Chief Executive Officer | 2,337,166 | May 22, 2026 |
| Kristin England | Chief Administrative Officer | 153,780 | Apr 23, 2026 |
| Jeffrey Langsam | Chief Clinical Officer | 127,650 | Apr 23, 2026 |
| Jeremy Castle | Chief Operating Officer | 247,031 | May 22, 2025 |
| Brad Hively | Director | 411,976 | Aug 24, 2026 |
| Anne McGeorge | Director | 332,535 | Jul 29, 2026 |
| Mohit Kaushal | Director | 205,716 | Jul 29, 2026 |
| Mark Stolper | Director | 56,957 | Jul 29, 2026 |
| Kimberly Jo Tzoumakas | Director | 46,301 | Jul 29, 2026 |
| Karen Marie Johnson | Director | 319,410 | Jul 29, 2026 |
| Mark L. Pacala | Director | 511,852 | Jul 29, 2026 |
| Gabriel Ling | Director | 296,502 | Dec 1, 2025 |
| Toi M, Llc | Director | 7,944,207 | Nov 20, 2025 |
| Growth I. L.P. M33 | Director | 16,420,701 | Nov 20, 2025 |
| Growth I. GP LLC M33 | Director | 8,523,281 | Nov 20, 2025 |
| Richard A. Barasch | Director | 4,571,022 | Aug 14, 2025 |
| Jorey Chernett | 10% owner | 10,660,858 | Aug 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brad Hively Director | Aug 21, 2026 | Sale(10b5-1 plan) | −298,853 | $6.51 | $1.95M | 411,976 |
| Jorey Chernett 10% owner | Aug 14, 2026 | Buy | +12,000 | $6.54 | $78.48K | 10,660,858 |
| Brad Hively Director | Jul 27, 2026 | Award | +27,108 | – | – | 710,829 |
| Mark L. Pacala Director | Jul 27, 2026 | Award | +30,120 | – | – | 286,881 |
| Karen Marie Johnson Director | Jul 27, 2026 | Award | +31,124 | – | – | 319,410 |
| Kimberly Jo Tzoumakas Director | Jul 27, 2026 | Award | +29,116 | – | – | 46,301 |
| Mark Stolper Director | Jul 27, 2026 | Award | +31,124 | – | – | 56,957 |
| Mohit Kaushal Director | Jul 27, 2026 | Award | +33,133 | – | – | 205,716 |
| Anne McGeorge Director | Jul 27, 2026 | Award | +41,165 | – | – | 332,535 |
| Jorey Chernett 10% owner | Jul 21, 2026 | Buy | +18,000 | $5.27 | $94.86K | 10,648,858 |
| Yale Podnos Chief Medical Officer | Jul 14, 2026 | Option exercise | +17,974 | $1.87 | $33.61K | 277,501 |
| Yale Podnos Chief Medical Officer | Jul 14, 2026 | Sale(10b5-1 plan) | −17,974 | $6.43 | $115.57K | 259,527 |
| Yale Podnos Chief Medical Officer | Jul 14, 2026 | Sale(10b5-1 plan) | −5,478 | $6.35 | $34.79K | 259,527 |
| Yale Podnos Chief Medical Officer | Jul 14, 2026 | Option exercise | +5,478 | $2.00 | $10.96K | 265,005 |
| Jorey Chernett 10% owner | Jul 10, 2026 | Buy | +15,000 | $5.85 | $87.75K | 10,630,858 |
| Kimberly Jo Tzoumakas Director | Jul 7, 2026 | Award | +17,185 | – | – | 17,185 |
| Mark Stolper Director | Jul 7, 2026 | Award | +25,833 | – | – | 25,833 |
| Jorey Chernett 10% owner | Jun 23, 2026 | Buy | +18,000 | $5.02 | $90.36K | 10,615,858 |
| Yale Podnos Chief Medical Officer | Jun 8, 2026 | Sale(10b5-1 plan) | −23,451 | $5.38 | $126.17K | 259,527 |
| Jorey Chernett 10% owner | Jun 4, 2026 | Buy | +12,000 | $4.75 | $57.00K | 10,579,858 |
| Robert Ross Carter Chief Financial Officer | May 21, 2026 | Other | −1,604 | $4.47 | $7.17K | 414,801 |
| Daniel Virnich Chief Executive Officer | May 21, 2026 | Other | −23,058 | $4.47 | $103.07K | 2,337,166 |
| Yale Podnos Chief Medical Officer | May 21, 2026 | Other | −1,805 | $4.47 | $8.07K | 282,978 |
| Jorey Chernett 10% owner | May 20, 2026 | Buy | +33,500 | $4.07 | $136.35K | 10,567,858 |
| Jorey Chernett 10% owner | May 19, 2026 | Buy | +5,000 | $4.05 | $20.25K | 10,534,358 |
| Jorey Chernett 10% owner | May 19, 2026 | Buy | +30,000 | $4.09 | $122.70K | 10,529,358 |
| Mohit Kaushal Director | Apr 16, 2026 | Sale(10b5-1 plan) | −38,433 | $3.50 | $134.52K | 172,583 |
| Mohit Kaushal Director | Apr 14, 2026 | Sale(10b5-1 plan) | −57,286 | $3.50 | $200.50K | 211,016 |
| Jorey Chernett 10% owner | Apr 9, 2026 | Buy | +20,000 | $3.10 | $62.00K | 10,499,358 |
| Daniel Virnich Chief Executive Officer | Mar 27, 2026 | Other | −98,534 | $3.07 | $302.50K | 2,360,224 |
| Daniel Virnich Chief Executive Officer | Mar 27, 2026 | Award | −670,608 | – | – | 2,458,758 |
| Yale Podnos Chief Medical Officer | Mar 27, 2026 | Other | −16,173 | $3.07 | $49.65K | 284,783 |
| Yale Podnos Chief Medical Officer | Mar 27, 2026 | Award | +66,446 | – | – | 300,956 |
| Robert Ross Carter Chief Financial Officer | Mar 27, 2026 | Other | −20,320 | $3.07 | $62.38K | 416,405 |
| Robert Ross Carter Chief Financial Officer | Mar 27, 2026 | Award | −202,914 | – | – | 436,725 |
| Jeffrey Langsam Chief Clinical Officer | Mar 27, 2026 | Award | +70,270 | – | – | 127,650 |
| Kristin England Chief Administrative Officer | Mar 27, 2026 | Award | +55,743 | – | – | 153,780 |
| Jorey Chernett 10% owner | Mar 27, 2026 | Buy | +27,429 | $2.96 | $81.19K | 10,479,358 |
| Jorey Chernett 10% owner | Mar 26, 2026 | Buy | +50,000 | $3.15 | $157.50K | 10,451,929 |
| Jorey Chernett 10% owner | Mar 24, 2026 | Buy | +125,000 | $3.11 | $388.75K | 10,401,929 |
| Jorey Chernett 10% owner | Mar 20, 2026 | Buy | +25,000 | $3.35 | $83.75K | 10,276,929 |
| Robert Ross Carter Chief Financial Officer | Mar 17, 2026 | Other | −1,314 | $3.59 | $4.72K | 233,811 |
| Yale Podnos Chief Medical Officer | Mar 17, 2026 | Other | −3,420 | $3.59 | $12.28K | 234,510 |
| Daniel Virnich Chief Executive Officer | Mar 17, 2026 | Other | −11,834 | $3.59 | $42.48K | 1,788,150 |
| Jorey Chernett 10% owner | Mar 17, 2026 | Buy | +75,000 | $3.42 | $256.50K | 10,251,929 |
| Jorey Chernett 10% owner | Mar 16, 2026 | Buy | +60,985 | $3.29 | $200.64K | 10,176,929 |
| Jorey Chernett 10% owner | Mar 13, 2026 | Buy | +263,000 | $2.92 | $767.96K | 10,115,944 |
| Robert Ross Carter Chief Financial Officer | Jan 2, 2026 | Other | −244 | $3.67 | $895 | 235,125 |
| Robert Ross Carter Chief Financial Officer | Jan 2, 2026 | Sale | −247 | $3.56 | $879 | 235,122 |
| Brad Hively Director | Dec 15, 2025 | Sale | −13,333 | $3.77 | $50.27K | 683,721 |
| Anne McGeorge Director | Nov 20, 2025 | Award | +40,123 | – | – | 291,370 |
| Anne McGeorge Director | Nov 20, 2025 | Award | +67,901 | – | – | 251,247 |
| Gabriel Ling Director | Nov 20, 2025 | Award | +46,296 | – | – | 296,502 |
| Gabriel Ling Director | Nov 20, 2025 | Award | +37,037 | – | – | 333,539 |
| Brad Hively Director | Nov 20, 2025 | Award | +41,667 | – | – | 664,647 |
| Brad Hively Director | Nov 20, 2025 | Award | +32,407 | – | – | 697,054 |
| Karen Marie Johnson Director | Nov 20, 2025 | Award | +47,840 | – | – | 251,249 |
| Karen Marie Johnson Director | Nov 20, 2025 | Award | +37,037 | – | – | 288,286 |
| Mark L. Pacala Director | Nov 20, 2025 | Award | +46,296 | – | – | 221,267 |
| Mark L. Pacala Director | Nov 20, 2025 | Award | +35,494 | – | – | 256,761 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Hively Bradford Director | Aug 21, 2026 | 298,853 | $1.95M | Aug 21, 2026 | Open Market Purchase |
| Podnos Yale Officer | Jul 14, 2026 | 23,452 | $146.58K | Jul 14, 2026 | Exercise of Stock Options |
| Podnos Yale Officer | Jun 8, 2026 | 23,451 | $114.21K | Jun 8, 2026 | Exercise of Stock Options |
| Kaushal Mohit Director | Apr 14, 2026 | 95,719 | $315.87K | Apr 14, 2026 | Restricted Stock Units |
| Daniel Hively Bradford Director | Dec 15, 2025 | 13,333 | $50.29K | Dec 15, 2025 | Restricted Stock |
| Pacala Mark Director | Nov 18, 2025 | 50,000 | $200.00K | Nov 18, 2025 | Restricted Stock |
| Toi M, Llc 10% Stockholder | Jun 5, 2025 | 127,207 | $407.06K | Jun 5, 2025 | SPAC PIPE |
| Growth I. L.P. M33 10% Stockholder | Jun 5, 2025 | 1,122,793 | $3.59M | Jun 5, 2025 | SPAC PIPE |
| Daniel Hively Bradford Director | Jun 3, 2025 | 1,936,537 | $5.56M | Jun 3, 2025 | Exercise of options under a registered plan |
| Daniel Hively Bradford Director | Jun 3, 2025 | 39,600 | $113.65K | Jun 3, 2025 | Restricted stock vesting under a registered plan |
| Growth I. L.P. M33 10% Stockholder | May 20, 2025 | 1,796,468 | $5.50M | May 20, 2025 | SPAC PIPE |
| Toi M, Llc 10% Stockholder | May 20, 2025 | 203,532 | $622.81K | May 20, 2025 | SPAC PIPE |
| Havencrest Healthcare Partners GP, LLC 10% Stockholder | Jan 19, 2024 | 80,000 | $171.20K | Jan 19, 2024 | Public stock issuance |
| Brad Hively Director | Nov 17, 2023 | 25,000 | $56.00K | Nov 17, 2023 | STOCK OPTION EXERCISE |
| Brad Hively Director | Nov 13, 2023 | 47,000 | $118.59K | Nov 13, 2023 | STOCK OPTION EXERCISE |